Nuria Pardo Aranda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nuria Pardo Aranda has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Mariscal Martínez
Unidad de Diagnóstico por la Imagen de la Mama, Servicio de Radiología, Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain
1 shared publication - Beatriz Cirauqui
Medical Oncology Department, Institut Català d'Oncologia, B-ARGO group, CARE program, IGTP, Badalona, Spain
1 shared publication - Clara Lezcano Rubio
Department of Pharmacy, Catalonian Institute of Oncology, Germans Trias i Pujol Hospital, Badalona, Spain
1 shared publication - Clara Rodríguez Caruncho
Servicio de Dermatología, Hospital Universitari Germans Trias i Pujol, Universitat Autónoma de Badalona, Badalona, Barcelona, Spain
1 shared publication - Iciar Pascual Miguel
Department of General and Digestive Surgery, Hospital Universitari Germans Trias I Pujol, Universitat Autònoma de Barcelona (UAB), 08916 Badalona, Spain
1 shared publication - Laia Capdevila
Hospital de Sant Pau i Santa Tecla, Tarragona, Tarragona, Spain
1 shared publication
Latest Publications
- Open Access
- 3 January 2014
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 8 (1) , 6
Nanoparticle albumin-bound paclitaxel in a patient with locally advanced breast cancer and taxane-induced skin toxicity: a case report
Taxanes have demonstrated effectiveness in the treatment of breast cancer, the most common type of cancer in women. The toxicity profile of taxanes (including skin toxicities) induces dose adjustment, delay, or discontinuation, which prevents a sufficient dose intensity to achieve a response. Nanoparticle albumin-bound paclitaxel, a solvent-free form of paclitaxel, prevents toxicities and reduces the pharmacokinetic interferences between paclitaxel and other drugs.
- 3 January 2014
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 8 (1) , 6
Open AccessNanoparticle albumin-bound paclitaxel in a patient with locally advanced breast cancer and taxane-induced skin toxicity: a case report
Taxanes have demonstrated effectiveness in the treatment of breast cancer, the most common type of cancer in women. The toxicity profile of taxanes (including skin toxicities) induces dose adjustment, delay, or discontinuation, which prevents a sufficient dose intensity to achieve a response. Nanoparticle albumin-bound paclitaxel, a solvent-free form of paclitaxel, prevents toxicities and reduces the pharmacokinetic interferences between paclitaxel and other drugs.